When Should I Get My Next COVID-19 Vaccine? Data From the Surveillance of Responses to COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED) Study
Authors' conclusion
Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses.
Study context
- Population
- Adults with immune-mediated inflammatory disease (IMID) (RA, inflammatory bowel disease, SLE, AS and SpA, psoriasis and PsA) after COVID-19 vaccination
- Outcome
- Serologic response: log-transformed anti-RBD IgG titers; Antinucleocapsid (anti-N) IgG also measured
- Follow-up
- Enrollment, 2 to 4 weeks and 3, 6, and 12 months after latest vaccine dose
Methodological detailspan-Canadian, multivariate generalized estimating equation regressions
- pan-Canadian
- Multivariate generalized estimating equation regressions
Main finding
As reported in the abstract
Factors associated with log-transformed anti-RBD titers
- Positive associations with female sex, number of doses, and self-reported COVID-19 infections in 2021 to 2023
- Negative associations with prednisone, anti-TNF agents, and rituximab
- Time since last vaccination negatively associated, particularly after 210 days
Observational data: associations, not effects.
Further findings
- Anti-N positivity associated with a self-reported infection in the 3 months prior to testing
- 94%
- Anti-N positivity, March 2021 to February 2022
- 5% to 15%
- Anti-N positivity as of March 2023 (post-Omicron)
- 30% to 35% or higher
- Anti-N positivity in IMID remained lower than Canada's general population seroprevalence (> 50% in 2022 and > 75% in 2023)
Original publication
When Should I Get My Next COVID-19 Vaccine? Data From the Surveillance of Responses to COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED) Study. J Rheumatol. Published 15 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →